Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Current Assets: 2020-2024

Historic Current Assets for Caribou Biosciences (CRBU) over the last 5 years, with Dec 2024 value amounting to $219.4 million.

  • Caribou Biosciences' Current Assets fell 34.50% to $155.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $155.5 million, marking a year-over-year decrease of 34.50%. This contributed to the annual value of $219.4 million for FY2024, which is 35.26% down from last year.
  • Per Caribou Biosciences' latest filing, its Current Assets stood at $219.4 million for FY2024, which was down 35.26% from $338.8 million recorded in FY2023.
  • Caribou Biosciences' 5-year Current Assets high stood at $391.2 million for FY2021, and its period low was $24.3 million during FY2020.
  • Over the past 3 years, Caribou Biosciences' median Current Assets value was $260.2 million (recorded in 2022), while the average stood at $272.8 million.
  • As far as peak fluctuations go, Caribou Biosciences' Current Assets skyrocketed by 1,509.45% in 2021, and later plummeted by 35.26% in 2024.
  • Yearly analysis of 5 years shows Caribou Biosciences' Current Assets stood at $24.3 million in 2020, then soared by 1,509.45% to $391.2 million in 2021, then crashed by 33.47% to $260.2 million in 2022, then spiked by 30.20% to $338.8 million in 2023, then plummeted by 35.26% to $219.4 million in 2024.